Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Michael DeMarco (42) erinnert sich kaum ... 2014 zugetragen hat. Seine Tochter Aly Demarco (13) wird ... - http://youtu.be/5cVoMCe0uiE „Man hat ... zu machen", erzählt Michael DeMarco . „Meine Frau ... Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, stand ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
(Date:11/21/2014)... 2014   Wellcentive , the industry leader ... organizations, announced today being named one of the ... Award .  Sponsored by Intel, the world leader ... year, recognizes companies developing leading-edge technology and unique ... Wellcentive,s Mason Beard , ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... activity reported against CTCL, PTCL and Ovarian ... -- CuraGen,Corporation , a clinical-stage biopharmaceutical company ... the clinical development,program for belinostat, a histone ... clinical activity of belinostat,against cutaneous T-cell lymphoma ...
... 12, 2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) today ... III clinical trial of ZYFLO CR(TM),(zileuton) extended-release tablets ... Asthma. ZYFLO CR was approved by the U.S. ... Critical Therapeutics,together with its co-promotion partner Dey, L.P. ...
Cached Medicine Technology:CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:11/23/2014)... To show thanks to new and old customers, ... evening dresses for weddings. Customers who need custom outfits ... a distinguished dress manufacturer, and it is among the ones ... a very long time. The CEO of this company says, ... able to buy not only a beautiful dress, but also ...
(Date:11/23/2014)... 2014 “BlackVue” was featured on NewsWatch ... which features the latest and coolest technology products available ... for NewsWatch, conducted the product review and shared with ... options in the car camera industry. , The need ... be hard to find the one that’s right per ...
(Date:11/23/2014)... 2014 Today Zane Benefits, the ... businesses, announced their new on demand webinar which ... Health Insurance. , According to Zane ... risk facing most American families. It is also ... large, when it comes to recruiting and retaining ...
(Date:11/22/2014)... 23, 2014 Recently, UWDress.com, a successful wedding ... wedding guest attire in order to prepare for the ... up to 70% off. , UWDress.com is a reliable ... very beautiful, especially the new items -- formal wedding guest ... the current market, including superstar and princess. As one of ...
(Date:11/22/2014)... 2014 Setria® Glutathione is now ... it for use “as a therapeutically active ingredient ... the Therapeutic Goods (Listing) Notice 2014 (No. 5) ... Setria® Glutathione will be exclusivity distributed in Australia ... and imports fine chemicals to Australian manufacturers. TGA ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... University of Illinois at Chicago College of Nursing has ... to improve the early growth and development of premature ... as poverty or minority status. , "Approximately half a ... United States," said Rosemary White-Traut, head of maternal-child nursing ...
... protein would let it thrive in upper airway, scientists say ... they,ve spotted a crucial step the deadly H5N1 bird flu ... , Since H5N1 first appeared in 1997, there have been ... Most of the human infections were the result of close ...
... EXCHANGE AND ... ELECTRONIC SUBMISSIONS, FOSTER ... its PC-LDM(TM) Suite that allows Pharmaceutical and,Biotechnology companies to instantly ... CDISC (Clinical Data Interchange,Standards Consortium) standard. FDA is anticipating that ...
... 50-70 million,sufferers, sleep disorders are one of the most ... Center on Sleep Disorder,Research. It should come as no ... disorders grows, so too does the market for,prescription sleep ... CNNMoney.com, the market for insomnia medications now tops $2,billion ...
... trouble, researchers note , THURSDAY, Oct. 4 (HealthDay ... Children,s Hospital Boston have found new information that ... a lung disease that affects premature newborns , ... or treat BPD, which can cause long-term breathing ...
... Smooth talking Mitt,Romney is heading back to the ... Bush,s veto of legislation that would provide health ... USA, September 25,2007] Despite recent polls showing that ... have provided health insurance to 10 million children,across ...
Cached Medicine News:Health News:$4 million nursing grant focuses on at-risk premature infants 2Health News:PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments 2Health News:Sleep Disorders: Waking Up to Reality 2Health News:Genes Give Clues to Newborn Lung Disease 2Health News:DNC: Romney an (S)CHIP Off the Bush Republican Block 2Health News:DNC: Romney an (S)CHIP Off the Bush Republican Block 3
... The STart 4 semi-automated hemostasis analyzer ... electro-mechanical clot detection (Viscosity-based Detection System). ... icteric or other optically turbid samples ... offers programmable and preprogrammed assays with ...
... The STA is a fully-automated, ... chromogenic and immunological assays in true ... method of sample management offers high ... samples without the need to interrupt ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
... The Electra 1800C is ... system that maximizes efficiency ... to the operator with ... is equipped with an ...
Medicine Products: